Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  

In this article

Eli Lilly

on Thursday said its next-generation obesity drug delivered strong weight loss and reduced knee arthritis pain in a late-stage study, clearing the first of several upcoming trials on the weekly injection.

The highest dose of the drug helped patients with obesity and a type of knee arthritis lose an average of 23.7% of their body weight at 68 weeks, when analyzing all participants, including those who discontinued treatment.

When evaluating only patients who stayed on the drug – essentially the best-case scenario – the highest dose delivered 28.7% weight loss on average.